Adhera Therapeutics (ATRX) 10-Q2008 Q1 Quarterly report

Filed: 8 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, Abbott, abdomen, acid, acquiree, ADA, Addendum, addressed, advantage, advisor, Agency, aggression, agonist, anabolic, animal, antidiabetic, apnea, artery, ASD, asthma, attention, AUC, authoritative, autistic, Bank, billion, biochemical, biology, biotech, bladder, Bloom, BMD, BMO, breast, Bruce, Byetta, caloric, calorie, cancer, cardiovascular, carefully, challenged, chemical, chicken, children, Cincinnati, Cmax, Code, colon, combination, combined, comprised, consume, contemplating, content, contraindicated, cooperation, coronary, country, death, declining, deconsolidated, deconsolidation, deferral, demand, density, description, developmental, diagnosed, diary, Dicer, died, directly, discretionary, disposed, distinguish, doubled, drawback, eating, economic, efficiently, elderly, elevated, endocrine, endometrial, England, environment, equivalence, equivalent, Escrow, Europe, European, eventually, explore, face, factor, fail, Fargo, FAS, fasting, fewer, firm, flow, foregoing, formal, formation, found, fracture, fragment, frequency, fundamental, gain, gall, gifted, gland, goodwill, grow, growing, gut, hemophilia, hierarchy, hip, history, Hologic, home, hospitalization, hypertension, identical, immunity, impair, impaired, impairment, implement, implemented, implementing, impracticable, incretin, indirect, indirectly, individual, induce, inhibit, intervention, inThe, intranasal, introduction, invasive, ischemic, IX, Journal, kidney, labeled, larger, learning, leaving, lengthy, literature, litigation, lived, long, lost, low, mainstay, marker, Mayo, men, mineral, modification, modulating, Noncontrolling, observable, obstructive, Organization, outcome, overcome, overweight, parent, past, pathological, PCT, people, pharmacological, PK, play, population, post, potency, prescription, prevalence, principle, problem, Promissory, proposed, prove, published, quoted, rational, receptor, relevance, relevant, remodeling, removed, renegotiating, resorption, respond, restoring, restructure, restructuring, retrospective, Revolving, ribonucleic, Roche, role, routinely, RSV, satiety, scope, seasonal, secretion, secured, Security, service, short, show, showed, shown, signature, Similarly, single, skeleton, sleep, slightly, slower, social, soluble, solution, Spanish, spectrum, spinal, Stephen, stimulation, strain, streamlined, strength, stroke, sudden, suffer, sugar, Surgeon, Syncytial, syndrome, theNational, therapy, thigh, thyroid, track, Treaty, twelve, unadjusted, underlying, unmet, Unobservable, unusual, vaccine, verified, version, Volume, women, workforce, world, Xenical

Removed: accelerate, achieved, advertising, AG, agreed, anticipated, approvable, assume, assumption, audit, avoidance, begin, belief, borrowing, brain, bulk, chlorobutanol, collaborate, collectively, commercializing, comparability, conducting, conform, cumulative, deny, diverse, eligible, enhance, escalating, examination, execution, exploit, fight, FIN, infrastructure, integrity, internally, interpretation, involved, jurisdiction, law, leasehold, Leveraging, lot, maintained, manufacturer, measurement, moderately, onForm, petitioner, pharmacokinetic, presenting, preservative, President, previously, proceed, promotion, quality, ranging, receivable, receiving, recording, replicate, replication, requested, responsible, reviewing, scientific, silence, stating, strategically, sustained, technical, threshold, transition, unused, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ATRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bruce R. York, Chief Financial Officer of Nastech Pharmaceutical Company Inc. (“Nastech”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Nastech on Form 10-Q for the fiscal quarter ended March 31, 2008 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Nastech.

Date: May 8, 2008



By:		/s/ Bruce R. York
		Name: Bruce R. York
		Title: Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Nastech and will be retained by Nastech and furnished to the Securities Exchange Commission or its staff upon request.

This certification accompanies each periodic report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by Nastech for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.